Pancreatic adenocarcinoma (PDAC) which were deemed borderline resectable through preoperative imaging due to abutment of the major artery, including the superior mesenteric artery (SMA) or common hepatic artery (CHA).
Conditions
Interventions
Sponsors
Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Histologically proven pancreatic adenocarcinoma (2) Age between 20 and 85 years (3) ECOG performance status of 0 or 1 (4) Borderline resectable pancreatic cancer (NCCN criteria) (5) abutment with the SMA or CHA (6) Adequate hematologic, renal, hepatic and respiratory function (7) Written informed consent
Exclusion criteria
Exclusion criteria: (1) Resectable or unresectable pancreatic cancer (NCCN criteria) (2)Tumors with encasement or stenosis of the arteries, those abutted with the celiac axis, and those only defined as BR diseases because of the superior mesenteric vein/PV factor (3) Hematologic, renal, hepatic and respiratory dysfunction (4)Active infections (5) Severe cardiac disorder, renal disorder, liver disorder, ulcer with bleeding, intestinal tract paralysis, uncontrollable diabetes mellitus (6) Presence of pleural effusion or ascites requiring drainage (7)Pregnant females or nursing mothers who can not stop lactation. Patients or partners, who don't attempt to doing contraception during the study period. (8) Severe mental disorder (9) Severe drug hypersensitivity (10) As determined by the principal investigator or the sub-investigator the subject is not adequate to participate in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Survival, short-term clinic benefit, the effect of NACRT, adverse events | — |
Countries
Japan
Contacts
Public ContactTsutomu Fujii
Nagoya University Graduate School of Medicine Gastroenterological Surgery (Surgery II)
Outcome results
None listed